Nova Allegro HbA1c Assay, Nova Allegro Analyzer
Assay, Glycosylated Hemoglobin. 510(k) K221326, from Nova Biomedical Corporation (Walham, MA). Product code LCP, class 2.
As of Nov 20, 2026, K221326 is an FDA 510(k) held by Nova Biomedical Corporation, substantially equivalent on Nov 22, 2024 after 931 days, with no recalls tied to it in FDA's recall database.
- Review time: 931 days
- Recalls: 0
The Nova Allegro HbA1c Assay is intended for in vitro diagnostic use on the Nova Allegro Analyzer for the quantitative determination of the glycated Hemoglobin (% hemoglobin A1c) in capillary whole blood obtained from the fingertip. The results from this assay are intended to be used for the monitoring of long-term blood glucose/metabolic control in individuals with diabetes mellitus.
- Alere Afinion HbA1c and ACR on Afinion 2 analyzerK171650 · Abbott Rapid Diagnostics · Nov 21, 2017
- Q-Pad Test SystemK231465 · Qurasense · Dec 6, 2023
- Document
- 510(k) summary (PDF) ↗
- Type
- Dual Track
- Received
- May 6, 2022
- Review panel
- Hematology
- Regulation
- 21 CFR 864.7470
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files